NEW YORK (GenomeWeb News) – Lentigen has licensed an HIV-related lentiviral vector technology patent held by the University of Cambridge, the company said today.
 
Baltimore-based Lentigen signed an exclusive agreement with Cambridge Enterprise, the technology licensing arm of the University of Cambridge, for technology that was developed by Andrew Lever.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.